Cargando…

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy

The blockade of immunological negative regulators offered a novel therapeutic approach that revolutionized the immunotherapy of cancer. Still, a significant portion of patients fail to respond to anti-PD-1/PD-L1 and/or anti-CTLA-4 therapy or experience significant adverse effects. We propose that on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steingold, Joseph M., Hatfield, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553081/ https://www.ncbi.nlm.nih.gov/pubmed/33117358 http://dx.doi.org/10.3389/fimmu.2020.570041

Ejemplares similares

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy
por: Liu, Zhaoyun, et al.
Publicado: (2022)

The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis
por: Duarte-Silva, Eduardo, et al.
Publicado: (2022)

Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma
por: Jin, Ketao, et al.
Publicado: (2021)

From ‘Hellstrom Paradox–to anti-adenosinergic cancer immunotherapy
por: Lukashev, Dmitriy, et al.
Publicado: (2007)

Adenosinergic Signaling Alters Natural Killer Cell Functional Responses
por: Chambers, Andrea M., et al.
Publicado: (2018)

The adenosinergic machinery in cancer: In-tandem insights from basic mechanisms to therapy
por: Kang, Chifei, et al.
Publicado: (2023)

Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy
por: Li, Yiliang, et al.
Publicado: (2018)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

Antitumoral Action of Resveratrol Through Adenosinergic Signaling in C6 Glioma Cells
por: Sánchez-Melgar, Alejandro, et al.
Publicado: (2021)

Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment
por: Liu, Yushuai, et al.
Publicado: (2022)

Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
por: Wei, Jinfen, et al.
Publicado: (2022)

The Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
por: Janji, Bassam, et al.
Publicado: (2022)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

The Adenosinergic System in Diabetic Retinopathy
por: Vindeirinho, J., et al.
Publicado: (2016)

Purinergic and Adenosinergic Signaling in Pancreatobiliary Diseases
por: Faraoni, Erika Y., et al.
Publicado: (2022)

Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?
por: Colbeck, Emily Jayne, et al.
Publicado: (2017)

The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
por: Abou Khouzam, Raefa, et al.
Publicado: (2022)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
por: Paladhi, Ankush, et al.
Publicado: (2022)

A New Drug Design Targeting the Adenosinergic System for Huntington's Disease
por: Huang, Nai-Kuei, et al.
Publicado: (2011)

The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer’s Disease
por: Cellai, Lucrezia, et al.
Publicado: (2018)

The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges
por: Sousa, Joana Beatriz, et al.
Publicado: (2017)

Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma
por: Xia, Yidan, et al.
Publicado: (2022)

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
por: Finisguerra, Veronica, et al.
Publicado: (2023)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
por: Horenstein, Alberto L., et al.
Publicado: (2019)

The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy
por: Asiry, Saeed, et al.
Publicado: (2021)

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Xing, Rui, et al.
Publicado: (2021)

Adenosinergic Pathway and Linked Suppression: Two Critical Suppressive Mechanisms of Human Donor Antigen Specific Regulatory T Cell Lines Expanded Post Transplant
por: Tripathi, Sudipta, et al.
Publicado: (2022)

An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment
por: Abou Khouzam, Raefa, et al.
Publicado: (2021)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

The role of adenosinergic pathway in human autoimmune diseases
por: Dong, Ke, et al.
Publicado: (2016)

Adenosinergic System and Neuroendocrine Syncope: What Is the Link?
por: Guieu, Régis, et al.
Publicado: (2023)

Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity
por: Dashtsoodol, Nyambayar, et al.
Publicado: (2017)

Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity
por: Azambuja, Juliana Hofstätter, et al.
Publicado: (2019)

Editorial: The Impact of Angiogenic Growth Factors and Hypoxia on the Antitumor Immune Response
por: Albonici, Loredana, et al.
Publicado: (2022)

Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy
por: Shafqat, Areez, et al.
Publicado: (2023)

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
por: Shevtsov, Maxim, et al.
Publicado: (2016)

Editorial: The immunosuppressive tumor microenvironment and strategies to revert its immune regulatory milieu for cancer immunotherapy
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r3ij6jumqr9tamodugodtkt3s9